Syndax Pharmaceuticals Inc
NASDAQ:SNDX

Watchlist Manager
Syndax Pharmaceuticals Inc Logo
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Watchlist
Price: 16.0679 USD 3% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Syndax Pharmaceuticals Inc?
Write Note

Intrinsic Value

SNDX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SNDX stock under the Base Case scenario is 16.2972 USD. Compared to the current market price of 16.0679 USD, Syndax Pharmaceuticals Inc is Undervalued by 1%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SNDX Intrinsic Value
16.2972 USD
Undervaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Syndax Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SNDX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SNDX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Syndax Pharmaceuticals Inc

Provide an overview of the primary business activities
of Syndax Pharmaceuticals Inc.

What unique competitive advantages
does Syndax Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Syndax Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Syndax Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Syndax Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Syndax Pharmaceuticals Inc.

Provide P/S
for Syndax Pharmaceuticals Inc.

Provide P/E
for Syndax Pharmaceuticals Inc.

Provide P/OCF
for Syndax Pharmaceuticals Inc.

Provide P/FCFE
for Syndax Pharmaceuticals Inc.

Provide P/B
for Syndax Pharmaceuticals Inc.

Provide EV/S
for Syndax Pharmaceuticals Inc.

Provide EV/GP
for Syndax Pharmaceuticals Inc.

Provide EV/EBITDA
for Syndax Pharmaceuticals Inc.

Provide EV/EBIT
for Syndax Pharmaceuticals Inc.

Provide EV/OCF
for Syndax Pharmaceuticals Inc.

Provide EV/FCFF
for Syndax Pharmaceuticals Inc.

Provide EV/IC
for Syndax Pharmaceuticals Inc.

Show me price targets
for Syndax Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Syndax Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Syndax Pharmaceuticals Inc?

What are the Net Income projections
for Syndax Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Syndax Pharmaceuticals Inc?

What are the EPS projections
for Syndax Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Syndax Pharmaceuticals Inc?

What are the EBIT projections
for Syndax Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Syndax Pharmaceuticals Inc?

Compare the revenue forecasts
for Syndax Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Syndax Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Syndax Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Syndax Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Syndax Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Syndax Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Syndax Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Syndax Pharmaceuticals Inc.

Provide ROE
for Syndax Pharmaceuticals Inc.

Provide ROA
for Syndax Pharmaceuticals Inc.

Provide ROIC
for Syndax Pharmaceuticals Inc.

Provide ROCE
for Syndax Pharmaceuticals Inc.

Provide Gross Margin
for Syndax Pharmaceuticals Inc.

Provide Operating Margin
for Syndax Pharmaceuticals Inc.

Provide Net Margin
for Syndax Pharmaceuticals Inc.

Provide FCF Margin
for Syndax Pharmaceuticals Inc.

Show all solvency ratios
for Syndax Pharmaceuticals Inc.

Provide D/E Ratio
for Syndax Pharmaceuticals Inc.

Provide D/A Ratio
for Syndax Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Syndax Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Syndax Pharmaceuticals Inc.

Provide Quick Ratio
for Syndax Pharmaceuticals Inc.

Provide Current Ratio
for Syndax Pharmaceuticals Inc.

Provide Cash Ratio
for Syndax Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Syndax Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Syndax Pharmaceuticals Inc?

What is the current Free Cash Flow
of Syndax Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Syndax Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Syndax Pharmaceuticals Inc

Current Assets 414.8m
Cash & Short-Term Investments 406.4m
Receivables 4.7m
Other Current Assets 3.7m
Non-Current Assets 11m
Long-Term Investments 10m
PP&E 756k
Other Non-Current Assets 217k
Current Liabilities 59.4m
Accounts Payable 4.9m
Accrued Liabilities 49m
Other Current Liabilities 5.5m
Non-Current Liabilities 2k
Long-Term Debt 2k
Efficiency

Earnings Waterfall
Syndax Pharmaceuticals Inc

Revenue
16m USD
Operating Expenses
-337.2m USD
Operating Income
-321.2m USD
Other Expenses
24.2m USD
Net Income
-297.1m USD

Free Cash Flow Analysis
Syndax Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SNDX Profitability Score
Profitability Due Diligence

Syndax Pharmaceuticals Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

16/100
Profitability
Score

Syndax Pharmaceuticals Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

SNDX Solvency Score
Solvency Due Diligence

Syndax Pharmaceuticals Inc's solvency score is 88/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
88/100
Solvency
Score

Syndax Pharmaceuticals Inc's solvency score is 88/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SNDX Price Targets Summary
Syndax Pharmaceuticals Inc

Wall Street analysts forecast SNDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SNDX is 37.1123 USD with a low forecast of 18.18 USD and a high forecast of 53.55 USD.

Lowest
Price Target
18.18 USD
13% Upside
Average
Price Target
37.1123 USD
131% Upside
Highest
Price Target
53.55 USD
233% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SNDX?

Click here to dive deeper.

Dividends

Syndax Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SNDX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SNDX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

SNDX News

Other Videos

Profile

Syndax Pharmaceuticals Inc Logo
Syndax Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.4B USD

Dividend Yield

0%

Description

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, engages in the development of cancer therapies. The company is headquartered in Waltham, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2016-03-03. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The firm is focused on developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1), protein for the treatment of MLL-rearranged (MLLr), acute leukemias and nucleophosmin 1 (NPM1), mutant acute myeloid leukemia (AML), as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative and breast cancer.

Contact

MASSACHUSETTS
Waltham
Building D, 35 Gatehouse Dr Fl 3
+17814191400.0
www.syndax.com

IPO

2016-03-03

Employees

59

Officers

CEO & Director
Mr. Michael A. Metzger M.B.A.
President, Head of Research & Development
Dr. Neil Gallagher M.D., Ph.D.
CFO, Treasurer & Chief Accounting Officer
Mr. Keith Alan Goldan CPA
Senior VP, General Counsel & Secretary
Mr. Luke J. Albrecht
Chief Medical Officer
Dr. Catherine Madigan M.D.
Co-Founder & Chief Scientific Officer
Dr. Peter Ordentlich B.Sc., Ph.D.
Show More
Co-Founder, Advisor and Chair of Scientific Advisory Board
Dr. Ronald M. Evans Ph.D.
Co-Founder
Dr. Michael Downes Ph.D.
Vice President of Investor Relations & Communications
Sharon Klahre
Show Less

See Also

Discover More
What is the Intrinsic Value of one SNDX stock?

The intrinsic value of one SNDX stock under the Base Case scenario is 16.2972 USD.

Is SNDX stock undervalued or overvalued?

Compared to the current market price of 16.0679 USD, Syndax Pharmaceuticals Inc is Undervalued by 1%.

Back to Top